IFX is a chimeric anti-TNF mAb approved for SpA, Crohn’s Disease (CD), psoriasis (Ps), psoriatic arthritis (PsA), RA, and ulcerative colitis (UC) [33]. This evidence concerns the gene TNF and Crohn disease.